In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Year: 2019
Type: review
Abstract: Carbapenem-resistant gram-negative bacteria including Enterobacteriaceae as well as nonfermenters, such as Pseudomonas aeruginosa and Acinetobacter baumannii, have emerged as significant global clinical threats. Although new agents have recently been approved, none are active across the entire range of resistance mechanisms presented by carbapenem-resistant gram-negative bacteria. Cefiderocol, a novel siderophore cephalosporin, has been shown in large surveillance programs and independent in vitro studies to be highly active against all key gram-negative causative pathogens isolated from patients with hospital-acquired or ventilator-associated pneumonia, bloodstream infections, or complicated urinary tract infections. The improved structure, the novel mode of entry into bacteria, and its stability against carbapenemases enables cefiderocol to exhibit high potency against isolates that produce carbapenemases of all classes or are resistant due to porin channel mutations and/or efflux pump overexpression. Resistance to cefiderocol is uncommon and appears to be multifactorial.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciz827
Author: Yoshinori Yamano
Institution: Shionogi (Japan)
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: cefiderocol, carbapenem-resistant Gram-negative bacteria, siderophore cephalosporin, efflux pump overexpression, Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, ventilator-associated pneumonia, bloodstream infection, complicated urinary tract infection, antibiotic resistance mechanisms
Open Access status: hybrid
Estimated APC paid: $4,763
Funder: Shionogi
OpenAlex ID: W2987071743
